To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
Dana-Farber Cancer Institute
Institute of Cancer Research, United Kingdom
M.D. Anderson Cancer Center
Acerta Pharma BV
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
Massachusetts General Hospital
AstraZeneca
University of Birmingham
University of Michigan Rogel Cancer Center
Assistance Publique Hopitaux De Marseille
Seoul National University Hospital